deListed Australia
Any AUS or NZ company

Browse Australian delisted companies

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Browse terminated Australian managed funds

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:


ASX Announcements (courtesy of ASX)


ASX, Legal & CGT Status


(updated at weekends)
Former (or subsequent) names
Shareholder links


Computershare Melbourne
Yarra Falls, 452 Johnston Street, Abbotsford VIC 3067
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 3 9473 2500
RegistryWebsite RegistryEmail

Company details
Address: Stem Cell Sciences (Australia) Pty Ltd , 2nd Floor, Building 75, Monash STRIP , Monash Uni, ClaytonCampus, Wellington Rd, CLAYTON , VIC, AUSTRALIA, 3800
Tel:  (03) 9905 0601 Fax: (03) 9824 6031

Date first listed: 16/04/2007

Sector: Pharmaceuticals & Biotechnology
Industry Group: XHJ
Activities: Stem cell research and development

name changed to Asset Realisation Company PLC


following completion of the sale of the trading subsidiaries of the Company and certain ancillary agreements, assets, properties and rights, the Company's name has now been changed to "Asset Realisation Company Plc". Please note that the Company's new website address is,


company advises of the completion of the disposal of the Trading Subsidiaries of the Company and certain ancillary agreements, assets, properties and rights (the "Disposal"), in accordance with the terms of the Disposal Agreement ( "Completion") - pursuant to the terms of the Disposal Agreement, the Company received at Completion: (i) 2,120,000 StemCells, Inc. Shares; (ii) a waiver of circa $715,000 (being the amount owed by the Company in respect of the StemCells, Inc. Loans); and (iii) the contingent right to receive up to 530,000 further Stem Cells, Inc. Shares subject to the terms of the escrow arrangements


company announces that at the Company's Extraordinary General Meeting ("EGM") held on Friday, all resolutions were duly approved by shareholders, present in person or by proxy, by 99% of the votes cast representing 64% of the total issued share capital


company announces that it has entered into a definitive agreement with StemCells, Inc. a publicly traded Delaware corporation (Nasdaq: STEM), for the sale of the Trading Subsidiaries of the Company and certain ancillary agreements, assets, properties and rights for a maximum total consideration of approximately US$4,849,000


provides Notice of an Extraordinary General Meeting of Stem Cell Sciences Plc, to be held at the offices of Daniel Stewart & Company Plc, 36 Old Jewry, London, EC2R 8DD, UK at 11.00 a.m. on 27 March 2009


the company will not be filing its preliminary results for the year ended 31st December 2008 - this is due to the Company considering an offer on its operating subsidiaries (Stem Cell Sciences Holdings Limited, Stem Cell Sciences Australia (Pty) Limited and Stem Cell Sciences UK Limited) - Stem Cell Sciences intends to remain suspended until further notice


directors believe that, given the current investment climate, the Company will deliver better shareholder value by selling substantially all of its operating assets and liabilities - a further announcement on this is expected to be made shortly


announces the signing of a further licence to its IRES technology - the undisclosed licensee is a major research-based international pharmaceutical company in the top 20 by market capitalisation and annual sales and it will use the technology in its own research and development activities - financial terms are not disclosed for this fully paid-up licence, which was signed during the Christmas holiday period


company announces that it has received 200,000 by way of a secured loan for working capital purposes - in exchange the third party lender has been granted a period of exclusivity to conduct further due diligence in respect of the Company's business and assets


the Company is still in discussions with a number of third parties about various options, including possible refinancing, divestiture of certain operations and/or merger opportunities of the Company, which may include an offer for the Company. There can be no certainty that any of the above transactions will proceed or that an offer will be made for the Company or as to the terms on which any such offer might be made. As a result of this announcement the Company is now in an Offer Period under the rules of the United Kingdom Takeover Code


the securities of Stem Cell Sciences Plc (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company


suspension of trading in the securities of Stem Cell Sciences Plc (the "Company") will be lifted immediately, following receipt of the Company's Full Year Accounts for the period ended 31 December 2007


shares suspended from quotation following failure to lodge full year accounts for the period ended 31 December 2007

View ASX Announcements (courtesy of ASX)


Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.


Company Updates
Post your comments here
Please read our Terms before posting comments.
    You can post a comment here about this company

    Please click in the "I'm not a robot" box. If an image appears, enter the word/figures you see in the image.

    loading Posting your comments. Please wait...

    Directors' on-market share transactions (last 5)


    Click here for the last 20 transactions all companies

    Directors & Executives (current)
    Alastair RiddellExecutive Director19/11/2007
    Sue FurberCompany Secretary
    David NewtonCompany Secretary

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    Date of first appointment, title may have changed.